Biohaven drops as US FDA seeks more BHV-7000 safety data
10/09/2026 12:43
BUZZ-Biohaven drops as US FDA seeks more BHV-7000 safety data ** Shares of drugmaker Biohaven BHVN.N fall 19.6% to $12.1 premarket
** Co's BHV-7000 program was partially placed on clinical hold after the FDA sought more information about a potential safety issue seen in animal studies
** The pause affects only new patient enrollment, while more than 600 patients already enrolled in the study can continue receiving treatment, co says
** BHV7000-303 remains on track to report topline data in the second half of 2026
** If losses hold, BHVN is set to open at its lowest level since mid-June
** 12 of 17 brokerages rate stock "buy" or higher, 4 "hold" and 1 "sell"; their median PT is $20 - data compiled by LSEG
** As of last close, BHVN stock up 32.9% YTD
(Reporting by Darshan Kumar in Bengaluru)
Recent news on Biohaven
See all newsBiohaven jumps as FDA takes second look at brain disorder drug
Brief: Biohaven Enters Strategic Licensing Agreement With Ono Pharma
Ono Pharma Announces An Exclusive License Agreement With Biohaven To Develop And Commercialize Igg Degraders In Japan, South Korea, Taiwan, And Asean
U.S. STOCKS ON THE MOVE-Macy's, American Eagle, Designer Brands
U.S. STOCKS ON THE MOVE-Copper miners, BKV, Kinetik